NoCOVImpact: Impact of COVID-19 Outbreak on Non-COVID-19 Patients

Sponsor
University Hospital, Geneva (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT04537559
Collaborator
La Tour Hospital (Other)
240,000
1
48
5003.4

Study Details

Study Description

Brief Summary

The Geneva Canton organized the health crisis of the COVID-19 epidemic around the care of COVID patients at the University Hospital (HUG), by moving the care of non-COVID patients to private hospitals of the canton. The COVID epidemic appears to have been associated with a decrease in consultations and care for non-COVID patients. An excess of morbidity and mortality (non-COVID) would be possible during or after the epidemic in connection with this "under-medicalization" of non-COVID patients.

The aim of this study is to measure and analyze the impact on the morbidity and mortality of inpatients during and after the COVID-19 epidemic in the adult inpatient wards of HUG and township hospitals / clinics.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The analysis of the various results will be carried out on all HUGs and on the various hospitals / clinics in the canton.

    A survival analysis for the outcome of death or rehospitalization will be performed, with a comparison according to each period.

    After epidemy evolution, finally, the outcomes will be compared between periods pre-COVID (from 01 march 2019 to 28 february 2020) versus per-COVID (01 march 2020 to 28 february 2022), and versus post-COVID (01 march 2022 to 28 february 2023). And comparaison would be performed between periods during the wave (per-wave) versus periods inter-wave.

    A description will be made in number (%) for numerical data and in median (IQR) for quantitative data. Univariate comparisons between the different periods will be carried out by statistical tests, parametric or not, adapted according to the data (Chi2 or Fisher's test for qualitative data, Student's test or Mann-Whitney-Wilcoxon for quantitative data). Statistical significance will be retained in the event of p <0.05.

    Multivariate analysis will be performed by logistic regression for the main outcome and by cox model for survival analysis. Different variables will be included in the models, including data on gender, age and comorbidity, as well as any variable having a difference with p <0.2 in univariate analysis.

    Secondary analyzes will be carried out by pathology (as the main diagnosis) according to the specific results defined for each situation. In retrospective analysis, these specific data will be relatively limited on the HUG area of full analysis brings together around total of 240,000 hospital stays. The main outcome data will be complete with no missing data. On the other hand, since this is retrospective data, it is possible that some important variables are missing. In this case, other patient data with missing data will not be included in the multivariate analyzes. In the event of missing data greater than 10%, a second sensitivity analysis may be performed after replacing the missing data with a multiple imputation method.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    240000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Impact of the COVID-19 Pandemic on the Morbidity and Mortality of Non-COVID-19 Patients Hospitalized Around the Epidemic Peak in the Geneva Area (Switzerland) (No COVID Impact)
    Actual Study Start Date :
    Mar 1, 2019
    Actual Primary Completion Date :
    Feb 28, 2022
    Anticipated Study Completion Date :
    Feb 28, 2023

    Arms and Interventions

    Arm Intervention/Treatment
    pre-COVID-19 period

    Patients hospitalized between 1.3.2019 and 28.02.2020

    per-COVID-19 period

    Patients hospitalized between 1.3.2020 and 28.02.2022

    post-COVID-19 period

    Patients hospitalized between 1.3.2022 and 28.02.2023

    Outcome Measures

    Primary Outcome Measures

    1. Intra-hospital mortality [Assessed at the discharge date, up to 3 months after admission]

      death during hospitalization of each patient

    2. composite outcome (worsening during hospitalization) [At the discharge date of hospitalization, up to 3 months after admission]

      intra-hospital mortality and / or transfer to intensive care and / or transfer to intermediate care during hospitalization

    Secondary Outcome Measures

    1. Pathologies leading to hospitalization [At the discharge date of hospitalization, up to 3 months after admission]

      Primary and secondary diagnosis during hospitalization (CIM10 codes)

    2. overall mortality at 3 months (90 days) [within the 3 months after the admission date]

      intra or extra hospital mortality : death occuring during hospitalization or after

    3. Potentially avoidable readmission rate [During the 30 days after the patient's discharge]

      Potentially avoidable readmission according to SQLape algorithm (http://www.sqlape.com/READMISSIONS.htm)

    4. mortality rate by pathology at 3 months [within the 3 months after the admission date]

      mortality for each top 10 of pathologies (intra or extra hospital mortality for each pathology)

    5. length of stay [At the discharge date of hospitalization, up to 3 months after admission]

      Hospital length of stay (Time between admission date and discharge date)

    6. rate of transfer to intermediate or intensive care [At the discharge date, up to 3 months after admission]

      Number of patients with transfer to intensive or intermediate care during hospitalization

    7. rate of transfer to rehabilitation care [At the discharge date of acute care, up to 3 months after admission]

      Number of patients with rehabilitation transfer during hospitalization

    8. specific gravity outcomes for patients with pneumonia : CURB 65 scale (Confusion, Urea, Respiratory rate, Blood pressure, Age [>65]) [At the acute care admission]

      CURB65 scale: min-max 0 to 5 points [5 points : worse outcome]

    9. specific gravity outcomes for patients with cardiac Failure : KILLIP class [At the acute care admission]

      KILLIP class (class 1 to 4) [class 4 : worse outcome]. The KILLIP classification is a system used in individuals with an acute myocardial infarction (heart attack), taking into account physical examination and the development of heart failure in order to predict and stratify their risk of mortality.

    10. specific gravity outcomes for patients with cardiac Failure : Weight variation [At the acute care admission]

      Weight variation : variation of weight at the admission compared to the basis weight

    11. specific gravity outcomes for patients with cardiac Failure or lung disease [At the acute care admission]

      FIO2 (% O2 prescribed): Fraction of inspired oxygen

    12. Leukocytes serum level [At the acute care admission]

      Giga / litre

    13. Polynuclear neutrophils serum level [At the acute care admission]

      Giga / litre

    14. Lymphocytes serum level [At the acute care admission]

      Giga / litre

    15. Hemoglobin serum level [At the acute care admission]

      gram/litre

    16. Thrombocytes serum level [At the acute care admission]

      Giga / litre

    17. Quick serum level [At the acute care admission]

      in %

    18. INR (International Normalized Ratio) [At the acute care admission]

      No unit

    19. fibrinogen serum level [At the acute care admission]

      gram/litre

    20. PTT serum level (partial Thromboplastin time) [At the acute care admission]

      in second

    21. D-Dimers serum level [At the acute care admission]

      ng / ml

    22. glucose serum level [At the acute care admission]

      mmol / litre

    23. glycated hemoglobin serum level (HbA1C) [At the acute care admission]

      in %

    24. C-reactive protein serum level (CRP) [At the acute care admission]

      mg / litre

    25. sodium serum level [At the acute care admission]

      mmol / l

    26. potassium serum level [At the acute care admission]

      mmol / l

    27. chlorides serum level [At the acute care admission]

      mmol / l

    28. calculated osmolality serum level [At the acute care admission]

      mOsm / kg

    29. Phosphates serum level [At the acute care admission]

      mmol / l

    30. corrected calcium serum level [At the acute care admission]

      mmol / l

    31. urea serum level [At the acute care admission]

      mmol / l

    32. creatinine serum level [At the acute care admission]

      µmol / l

    33. eGFR (CKD-EPI) serum level [At the acute care admission]

      ml / min / 1.73m2

    34. albumin serum level [At the acute care admission]

      g / l

    35. prealbumin serum level [At the acute care admission]

      mg / l

    36. cyanocobalamin serum level [At the acute care admission]

      pmol / l

    37. folate serum level [At the acute care admission]

      nmol / l

    38. 25-hydroxy vitamin D (D2 + D3) serum level [At the acute care admission]

      nmol / l

    39. proBNP (Brain Natriuretic Peptid) serum level [At the acute care admission]

      ng / l

    40. Ultra sensitive Troponin T serum level [At the acute care admission]

      ng / l

    41. ASAT (aspartate transaminase) serum level [At the acute care admission]

      U / l

    42. ALAT (alanine aminotransferase) serum level [At the acute care admission]

      U / l

    43. Alkaline phosphatases serum level [At the acute care admission]

      U / l

    44. Gamma glutamyl transpeptidase. serum level [At the acute care admission]

      U / l

    45. Total bilirubin serum level [At the acute care admission]

      µmol / l

    46. ferritin serum level [At the acute care admission]

      µg / l

    47. TSH serum level [At the acute care admission]

      mU / l

    48. Arterial pH [At the acute care admission]

      No unit

    49. Arterial pCO2 (carbon dioxide partial pressure) [At the acute care admission]

      kPa

    50. Arterial pO2 (oxygen partial pressure) [At the acute care admission]

      kPa

    51. Arterial lactate [At the acute care admission]

      mmol / l

    52. Arterial HCO3 (bicarbonate) [At the acute care admission]

      mmol / l

    53. protein serum level [At the acute care admission]

      g / l

    54. Arterial pressure [At the acute care admission]

      Arterial pression (min-max), in mmHg

    55. cardiac rates [At the acute care admission]

      Bat/mn

    56. respiratory rates [At the acute care admission]

      /mn

    57. temperature [At the acute care admission]

      Celsius degrees

    58. oxygen saturation [At the acute care admission]

      Percutaneous oxygen saturation (in %)

    59. peak flow [At the acute care admission]

      L/mn

    60. specific scales : VAS of pain [At the acute care admission]

      Visual analog Pain scale (min-max : 1 to 10 [worse outcome])

    61. specific scales : FIM [At the acute care admission]

      Functional Independence Measure (min-max : 18 [worse outcome]) to 126)

    62. specific scales : SOFA score [At the acute care admission]

      Sequential Organ Failure Assessment Score (min-max : 0 to 24 [worse outcome])

    63. specific scales : MNA [At the acute care admission]

      Mini Nutritional Assessment (min-max : 0 [worse outcome] to 14)

    64. specific scales : NRS [At the acute care admission]

      Nutrition Risk Screening (min-max : 0 to 12 [worse outcome])

    65. serum or urine positive bacteriologic sample [At the acute care admission or during hospitalization]

      number of positive hemoculture or urinary cultures

    66. Patient questionnaire [At the discharge date of hospitalization, up to 3 months after admission]

      Questionnaire asking each patient if they had difficulty seeing a doctor before their hospitalization and if they delayed their hospitalization due to the COVID-19 crisis.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    16 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patient hospitalized in an adult department

    • During the pre-period-COVID-19 period, the per-COVID-19 or the post-COVID-19 periods ie from the 1st march 2019 to 28 february 2023.

    Exclusion Criteria:
    • Patients who have been hospitalized for COVID-19 infection

    • Patients hospitalized in the Department of Adolescent Woman and Child, Department of Psychiatry or Intensive Care Department during the same periods.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Geneva University Hospital Geneva Canton De Genève Switzerland 1255

    Sponsors and Collaborators

    • University Hospital, Geneva
    • La Tour Hospital

    Investigators

    • Principal Investigator: Jerome Stirnemann, MD, University Hospital, Geneva

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Jerome Stirnemann, Dr, University Hospital, Geneva
    ClinicalTrials.gov Identifier:
    NCT04537559
    Other Study ID Numbers:
    • 2020-01017
    First Posted:
    Sep 3, 2020
    Last Update Posted:
    Mar 25, 2022
    Last Verified:
    Mar 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Jerome Stirnemann, Dr, University Hospital, Geneva
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 25, 2022